News Channels

24 Mar 2017 EPREX® (epoetin alfa) Marketing Authorisation Extended to Include Treatment of Symptomatic Anaemia in Patients with Low or Intermediate-1-Risk Myelodysplastic Syndromes
24 Mar 2017 Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease
24 Mar 2017 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy
24 Mar 2017 European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
24 Mar 2017 CHMP provides positive opinion for EU label update for Novo Nordisk's Tresiba® based on data from SWITCH trials
24 Mar 2017 Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B
24 Mar 2017 Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors
24 Mar 2017 PureTech Health Announces Licensing and Equity Agreement with Novartis to Advance Clinical Stage mTORC1 Programs
24 Mar 2017 C4 Therapeutics and Calico Enter Strategic Partnership to Discover Novel Therapeutics Based on Targeted Protein Degradation
24 Mar 2017 FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
24 Mar 2017 BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline
24 Mar 2017 Tessa Therapeutics Announces Acquisition of Euchloe Bio
24 Mar 2017 European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
24 Mar 2017 Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe
24 Mar 2017 FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
24 Mar 2017 ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest’s antibody-drug conjugate (BT-062)
23 Mar 2017 Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
23 Mar 2017 Medigene AG: Announces target and outlines design for its first clinical trial in TCR cancer immunotherapy (MDG1011)
23 Mar 2017 Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013
22 Mar 2017 Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing